💊🫀 Aspirin in the Crosshairs?

The AQUATIC Trial (NEJM, Aug 2025) raises sharp questions on dual-pathway therapy in chronic coronary syndrome (CCS) patients already on long-term anticoagulation.

📉 Adding aspirin led to:

• ↑ Ischemic events (HR 1.53; P=0.02)

• ↑ Mortality (HR 1.72; P=0.01)

• ↑ Major bleeding (HR 3.35; P)

🧠 Takeaway: More isn't always better.* In high-risk CCS, aspirin may harm more than help.

📚 Read: https://www.nejm.org/doi/full/10.1056/NEJMoa2507532

#Cardiology #Antiplatelet #NEJM #PrecisionMedicine #AQUATICTrial*